Evalstotug Drug Asset Due Diligence Report 2026

This Evalstotug Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Evalstotug can convert its Monoclonal antibody profile and CTLA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Evalstotug (query alias: Evalstotug)
Modality / target	Monoclonal antibody; CTLA4; CTLA4 inhibitors
Highest global status	Phase 2
Originator	BioAtla, Inc.
Active developers	BioAtla, Inc., Himalaya Therapeutics, BeOne Medicines Ltd.

The MCP disease footprint includes Melanoma, Non-Small Cell Lung Cancer, Non-small cell lung cancer stage IIIB. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05271604	Phase 2	Completed	42	Primary endpoint not disclosed in English source
NCT05180799	Phase 1/2	Active, not recruiting	320	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

497 Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: DCR = 52 %

Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Phase 1; n=18; evaluation: Positive. Reported fields: SD = 9 Pts

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Phase 1; n=18; evaluation: Positive. Reported fields: CR = 1 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Evalstotug addresses Melanoma, Non-Small Cell Lung Cancer, Non-small cell lung cancer stage IIIB. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-04-16	BioAtla Subsidiary, Himalaya Therapeutics, Will Develop And Commercialize CAB Products In Greater China Market	Preclinical	Financial terms not disclosed
2019-04-09	BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy	Not disclosed	US$20.0M upfront; US$249.0M milestones; US$269.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Gene signatures predictive of cancer cell response to immunomodulatory therapy”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination of PARP7 inhibitor combined medication, and use thereof in treating tumors”. The milestone feed surfaced a patent-application signal described as “Methods for treating calcitonin gene-related peptide (CGRP) - expressing cancers”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO